Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reissued by research analysts at B. Riley in a research report issued on Thursday. They presently have a $40.00 price objective on the stock. B. Riley’s price objective would indicate a potential upside of 293.31% from the stock’s current price.
Separately, Zacks Investment Research raised Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $24.38.
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) opened at $10.17 on Thursday. The company has a market capitalization of $248.05 and a P/E ratio of -3.59. Syndax Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $15.70.
Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its position in shares of Syndax Pharmaceuticals by 7.3% during the second quarter. FMR LLC now owns 1,341,644 shares of the company’s stock valued at $18,743,000 after acquiring an additional 91,328 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Syndax Pharmaceuticals by 25.1% during the second quarter. Vanguard Group Inc. now owns 512,624 shares of the company’s stock valued at $7,161,000 after acquiring an additional 102,700 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Syndax Pharmaceuticals by 11,266.0% during the second quarter. JPMorgan Chase & Co. now owns 439,070 shares of the company’s stock valued at $6,134,000 after acquiring an additional 435,207 shares during the last quarter. Alyeska Investment Group L.P. increased its position in shares of Syndax Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 330,910 shares of the company’s stock valued at $3,872,000 after acquiring an additional 5,910 shares during the last quarter. Finally, Tekla Capital Management LLC purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at approximately $2,794,000. 61.65% of the stock is owned by institutional investors.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.